Vogenx (NASDAQ:VOGX – Get Free Report) was upgraded by investment analysts at WBB Securities to a “moderate buy” rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports.
A number of other equities research analysts also recently weighed in on the company. Wall Street Zen raised Vogenx to a “hold” rating in a report on Saturday, August 22nd. JonesTrading initiated coverage on Vogenx in a report on Tuesday. They set a “buy” rating and a $55.00 price target for the company. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to data from MarketBeat, Vogenx currently has a consensus rating of “Strong Buy” and a consensus target price of $48.50.
Vogenx Price Performance
Vogenx Company Profile
Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.
Read More
- Five stocks we like better than Vogenx
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
